High-dose chemotherapy often requires hematopoietic progenitor cell reinfusion, but drugs
with extramedullary dose-limiting toxicity may be administered in the high-dose range by
simple growth factor support. In this study, we evaluated the feasibility and toxicity of a three-
drug high-dose regimen supported by recombinant human granulocyte colony-stimulating
factor (rhG-CSF). Ten patients with histologically proven malignancy were enrolled. Eight
had breast cancer, one non-Hodgkin's lymphoma, and one a mediastinal tumor of unknown …